AbbVie improperly blocked AndroGel competition: FTC

SHARE AbbVie improperly blocked AndroGel competition: FTC

AbbVie Inc. was accused Monday of filing baseless patent-infringement lawsuits to protect AndroGel from generic competition.

AbbVie and partner Besins Healthcare Inc. illegally blocked consumer access to lower-cost versions of the $1 billion-a-year testosterone replacement drug, the Federal Trade Commission alleges in a complaint filed Monday.

The FTC says AbbVie and Besins filed lawsuits against Teva Pharmaceuticals and Perrigo Co. to delay regulatory approval of generic versions of AndroGel. The FTC also alleges AbbVie improperly paid Teva to drop its countersuit and delay marketing of its competing product.

“The FTC is acting today to stop anticompetitive conduct by AbbVie, Besins Healthcare and Teva which has forced consumers to overpay hundreds of millions for the drug AndroGel,” FTC Chairwoman Edith Ramirez said in a news release.

“We cannot comment on the lawsuit specifically. However, our patent infringement lawsuits were appropriate and our settlement agreements were lawful, as well as in the best interest of all parties,” said Dirk Van Eeden, AbbVie senior director of public affairs.

AbbVie accused of improperly blocking AndroGel competition

The Latest
In fatal attacks this weekend, a woman was killed and a gunman was among two others wounded in a shootout Friday night in Chinatown, Chicago police said.
Leiter entered one out into the first inning and allowed one run and three hits in 5 1⁄3 innings in the Cubs’ 3-1 victory Saturday.
He’s confident the rehab start he will make with Triple-A Iowa on Sunday will be the only one he needs before returning.
The Bulls accomplished most of their major offseason goals in the last month. But while that should be a good thing, it might not be enough. The Eastern Conference is improving both ahead of and behind the Bulls.